Device that reverses Alzheimer’s cognitive decline may also increase human longevity

RF Longevity Founder Gary Arendash talks immunity, cytokines and increasing human longevity through bioengineering with FDA breakthrough tech.

Fourteen years ago, scientists discovered exposing transgenic mice with Alzheimer’s to RF waves produced some exciting results; not only were the mice protected from further cognitive decline, but older mice even experienced a reversal of cognitive impairment. It will come as no surprise that the researchers set about leveraging this tech for a human approach, developing a treatment called Transcranial Radiofrequency Wave Treatment (TRFT). RF Longevity has realized this therapy in a device called MemorEM, a patented, noninvasive technology that has received Breakthrough Device designation from the US FDA as a potential treatment for Alzheimer’s in humans.

My take on this: The MemorEM device delivers ultrahigh radio frequency electromagnetic waves to the brain via eight transmitters embedded in a cap and a control box worn on the arm. Users wear the device at home for an hour a day, and experience no sound or sensation associated with the device – they can pretty much get on with anything during this time, although perhaps not grab a shower!

We sat down with Dr Gary Arendash, founder of RF Longevity, to find out more about MemorEM’s potential for Alzheimer’s therapy and lifespan extension and why all roads for a life extending intervention must go through preventing or lessening dementia.

Gary Arendash on TRTF potential

Most importantly, the radio frequency rays that we’re using are very safe. To my mind, TRFT is a front runner among gerotherapeutics to extend human lifespan, and this is for a number of reasons.

First, TRFT was the first gerotherapeutic to be given breakthrough device designation by FDA against a major disease of aging. Second, TRFT stops and reverses a major disease of aging, namely Alzheimer’s disease, albeit in small clinical trials. Third, TREFT hasn’t shown any deleterious side effects in clinical trials – it’s actually been given non -significant risk designation in the United States.

And very importantly, with regards to longevity, in our Alzheimer’s subjects, and I am an Alzheimer’s researcher, TRFT, given over an extended two and a half year period of time, resulted in no new diseases of aging – and these folks averaged 70 years of age when they began the study. Finally, in our four clinical publications, we’ve identified three major mechanisms of action that we believe will collectively target diseases of aging, a number of them, and the aging process itself.

Explore RF Longevity, TRFT mechanisms and their impact on immunity, future health advancements and more, straight from Gary Arendash HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!